These findings indicate that specific suppression of ezrin might be a novel therapeutic strategy to suppress PD-L1 protein expression in human cervical cancer cells, which may in turn overcome the primary and adaptive resistance to PD-1/PD-L1 blockade therapies. This evidence concerns the gene CD274 and cervical carcinoma.